Regulus Therapeutics Inc.
(RGLS)
undefined
undefined%
At close: undefined
1.58
-0.32%
After-hours Dec 13, 2024, 04:00 PM EST
Company Description
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States.
Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.
The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies.
Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Regulus Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 9, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Joseph P. Hagan M.B.A. |
Contact Details
Address: 4224 Campus Point Court San Diego, California United States | |
| Website | https://www.regulusrx.com |
Stock Details
| Ticker Symbol | RGLS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001505512 |
| CUSIP Number | 75915K309 |
| ISIN Number | US75915K3095 |
| Employer ID | 26-4738379 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joseph P. Hagan M.B.A. | Chief Executive Officer & Director |
| Crispina Calsada CPA | Chief Financial Officer |
| Christopher Ray Aker J.D. | Senior Vice President, General Counsel & Corporate Secretary |
| Daniel J. Penksa | Vice President of Finance & Controller |
| Dr. Claire Susan Padgett M.S., M.T., Ph.D. | Senior Vice President of Clinical Operations |
| Dr. Preston S. Klassen M.D., M.H.S. | President, Head of Research & Development and Director |
| Dr. Rekha Garg M.D., M.S. | Chief Medical Officer |
| Edmund Lee Ph.D. | Vice President of Translational Medicine |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 07, 2024 | 10-Q | Quarterly Report |
| Nov 07, 2024 | 8-K | Current Report |
| Nov 04, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 24, 2024 | 8-K | Current Report |
| Oct 24, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |